BR9906735A - Composição farmacêutica lìquida aquosa - Google Patents

Composição farmacêutica lìquida aquosa

Info

Publication number
BR9906735A
BR9906735A BR9906735-8A BR9906735A BR9906735A BR 9906735 A BR9906735 A BR 9906735A BR 9906735 A BR9906735 A BR 9906735A BR 9906735 A BR9906735 A BR 9906735A
Authority
BR
Brazil
Prior art keywords
gatifloxacin
aqueous liquid
pharmaceutical composition
liquid pharmaceutical
salt
Prior art date
Application number
BR9906735-8A
Other languages
English (en)
Other versions
BRPI9906735B1 (pt
BRPI9906735B8 (pt
Inventor
Shinichi Yasueda
Katsuhiro Inada
Original Assignee
Senju Pharma Co
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16986030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9906735(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senju Pharma Co, Kyorin Seiyaku Kk filed Critical Senju Pharma Co
Publication of BR9906735A publication Critical patent/BR9906735A/pt
Publication of BRPI9906735B1 publication Critical patent/BRPI9906735B1/pt
Publication of BRPI9906735B8 publication Critical patent/BRPI9906735B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Patente de Invenção: <B>''COMPOSIçãO FARMACêUTICA LìQUIDA AQUOSA"<D>. é provida uma composição farmacêutica líquida aquosa, que compreende Gatifloxacin (nomenclatura química: ácido (±)-1-ciclopropil-6-flúor -1,4-diidro-8-metóxi-7-(3-metil-1-piperazinil)-4-oxo-3-quinolino carboxílico ou seu sal e edetato dissódico. Além disso, são providos um método para elevar a permeabilidade da córnea por meio de Gatifloxacin, um método para prevenção da precipitação de cristais de Gatifloxacin e um método para prevenção da coloração de Gatifloxacin mediante incorporação de edetato dissódico a uma preparação líquida aquosa contendo Gatifloxacin ou seu sal.
BRPI9906735A 1998-08-21 1999-08-20 'composição farmacêutica líquida aquosa e método para prevenção de precipitações de cristais e para prevenção da coloração de gatifloxacina.' BRPI9906735B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23543298 1998-08-21
PCT/JP1999/004483 WO2000010570A1 (fr) 1998-08-21 1999-08-20 Preparations liquides aqueuses

Publications (3)

Publication Number Publication Date
BR9906735A true BR9906735A (pt) 2000-08-15
BRPI9906735B1 BRPI9906735B1 (pt) 2015-09-01
BRPI9906735B8 BRPI9906735B8 (pt) 2021-05-25

Family

ID=16986030

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9906735A BRPI9906735B8 (pt) 1998-08-21 1999-08-20 'composição farmacêutica líquida aquosa e método para prevenção de precipitações de cristais e para prevenção da coloração de gatifloxacina.'

Country Status (17)

Country Link
US (1) US6333045B1 (pt)
EP (1) EP1025846B1 (pt)
JP (1) JP5138128B2 (pt)
KR (1) KR100595956B1 (pt)
CN (1) CN1133432C (pt)
AT (1) ATE332692T1 (pt)
AU (1) AU761040B2 (pt)
BR (1) BRPI9906735B8 (pt)
CA (1) CA2307632C (pt)
DE (1) DE69932313T2 (pt)
DK (1) DK1025846T3 (pt)
ES (1) ES2264266T3 (pt)
HK (1) HK1029934A1 (pt)
NZ (1) NZ504017A (pt)
PT (1) PT1025846E (pt)
TW (1) TW537895B (pt)
WO (1) WO2000010570A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
WO2001027103A1 (en) 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
AU2001230525A1 (en) 2000-02-01 2001-08-14 Kyorin Pharmaceutical Co. Ltd. Sulfate salt of quinolonecarboxylic acid derivative and use thereof
EP1560584B1 (en) 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Fab i inhibitors
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
WO2004052890A1 (en) 2002-12-06 2004-06-24 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
JP2005008625A (ja) * 2003-05-23 2005-01-13 Santen Pharmaceut Co Ltd キノロン系抗菌化合物を含有する点眼液
PT1828167E (pt) 2004-06-04 2014-10-08 Debiopharm Int Sa Derivados de acrilamida como agentes antibióticos
CN101137359B (zh) 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
CA2666440A1 (en) 2006-10-12 2008-04-17 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid preparation having improved intraocular gatifloxacin penetration
CA2666058A1 (en) * 2006-10-12 2008-04-17 Kyorin-Pharmaceutical Co., Ltd. Aqueous liquid preparation comprising gatifloxacin
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
CA2621616A1 (en) * 2007-02-19 2008-08-19 Alcon Research, Ltd. Topical gatifloxacin formulations
JP2008247828A (ja) * 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
JP5258331B2 (ja) * 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
MX2010010687A (es) * 2008-03-31 2011-02-24 Kyorin Seiyaku Kk Preparacion liquida acuosa que contiene gatifloxacina.
WO2009123098A1 (ja) * 2008-03-31 2009-10-08 杏林製薬株式会社 ガチフロキサシン含有水性液剤、その製造方法、および、該水性液剤の低温保存および凍結融解時の沈殿生成を抑制する方法
ES2809177T3 (es) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalación de levofloxacino para reducir la inflamación pulmonar
LT2344129T (lt) 2008-10-07 2018-05-10 Horizon Orphan Llc Aerozolinės fluorchinolono kompozicijos, skirtos farmakokinetikų pagerinimui
US20100209538A1 (en) * 2009-02-18 2010-08-19 Cipolla David C Ph-modulated formulations for pulmonary delivery
UA92423C2 (ru) * 2009-07-24 2010-10-25 Анатолій Альбертович Кузьмін Антибактериальная композиция
RU2563809C2 (ru) 2009-09-04 2015-09-20 Мпекс Фармасьютикалс, Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
CA2868390C (en) 2012-03-26 2020-03-31 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
ME03392B (me) 2012-06-19 2020-01-20 Debiopharm Int Sa Prolek derivati (e)-n-meтil-n-( (з-метi lbenzofuran-2-il)meтil)-3-(7 -okso-5 ,6, 7,8-тетrанidr0-1,8-nafтiridin-3-il)akrilamida
RS61312B1 (sr) 2016-02-26 2021-02-26 Debiopharm Int Sa Lek za lečenje infekcija dijabetskog stopala
JP6886322B2 (ja) * 2016-03-25 2021-06-16 興和株式会社 眼科用組成物
MX2019001633A (es) 2016-08-12 2019-09-18 Silk Tech Ltd Proteina derivada de la seda para el tratamiento de la inflamacion.
US12016855B2 (en) 2020-08-26 2024-06-25 Somerset Therapeutics, Llc Prednisolone and moxifloxacin compositions and methods
US11298315B2 (en) 2020-08-26 2022-04-12 Somerset Therapeutics, Llc. Triamcinolone and moxifloxacin compositions
US11484538B2 (en) 2020-08-26 2022-11-01 Somerset Therapeutics, Llc Bromfenac, prednisolone, and moxifloxacin compositions and methods
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU553415B2 (en) * 1983-09-19 1986-07-17 Abbott Japan Co., Ltd. 6-fluoro-1-4-dihydro-4-oxo-7-substituted piperazinyl- quinoline-3-carboxylic acids
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
JPH0696533B2 (ja) * 1987-01-14 1994-11-30 北陸製薬株式会社 キノロンカルボン酸の水性組成物
JP2549285B2 (ja) * 1987-02-02 1996-10-30 第一製薬株式会社 鼻用噴霧剤
JPH01258620A (ja) * 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd 耳疾患用局所製剤
JP3996659B2 (ja) * 1995-10-25 2007-10-24 千寿製薬株式会社 血管新生抑制剤
JPH09124484A (ja) * 1995-10-27 1997-05-13 Schering Purau Kk 点眼剤
AU5342498A (en) * 1997-01-10 1998-08-03 Wakamoto Pharmaceutical Co., Ltd. Difluprednate-containing ophthalmic o/w emulsion composition

Also Published As

Publication number Publication date
HK1029934A1 (en) 2001-04-20
KR100595956B1 (ko) 2006-07-03
EP1025846B1 (en) 2006-07-12
JP5138128B2 (ja) 2013-02-06
US6333045B1 (en) 2001-12-25
WO2000010570A1 (fr) 2000-03-02
ES2264266T3 (es) 2006-12-16
BRPI9906735B1 (pt) 2015-09-01
ATE332692T1 (de) 2006-08-15
PT1025846E (pt) 2006-10-31
DK1025846T3 (da) 2006-11-06
AU5302699A (en) 2000-03-14
EP1025846A4 (en) 2004-12-29
EP1025846A1 (en) 2000-08-09
AU761040B2 (en) 2003-05-29
CA2307632C (en) 2007-05-22
DE69932313D1 (de) 2006-08-24
NZ504017A (en) 2001-09-28
TW537895B (en) 2003-06-21
BRPI9906735B8 (pt) 2021-05-25
KR20010031240A (ko) 2001-04-16
CN1275081A (zh) 2000-11-29
CN1133432C (zh) 2004-01-07
DE69932313T2 (de) 2007-07-19
CA2307632A1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
BR9906735A (pt) Composição farmacêutica lìquida aquosa
PE20010400A1 (es) Formulacion de sal comun y moxifloxacina
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BR0313732A (pt) Compostos de pirimido tendo atividade antiproliferativa
NO941937L (no) Sakarinderivater som inhiberer proteolytiske enzymer
TR199500825A2 (tr) Cok üniteli farmasötik müstahzar.
EA200400432A1 (ru) Производные мочевины
NO308848B1 (no) Kromanforbindelse og farmasøytisk preparat som inneholder den
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
FI95773B (fi) Menetelmä vesipitoisen, N-(3,4-dimetoksikinnamoyyli)antraniilihappoa sisältävän farmaseuttisen koostumuksen valmistamiseksi
BR9407910A (pt) Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto
NO871059D0 (no) Nye carboxylsyrederivater, fremgangsmaate for fremstilling av disse, anvendelse derav, saa vel som legemidler inneholdende disse forbindelser.
ATE162081T1 (de) Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen
BR0208169A (pt) Composto quìmicos
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
BR0300698A (pt) Compostos derivados de quinazolina, um processo para sua preparação e composições farmacêuticas contendo-os
ATE410164T1 (de) Wässrige flüssige preparation von pranoprofen
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
ATE131044T1 (de) Stabilisator für eine 4-ethyl-2-hydroxyimino-5- nitro-3-hexenamide enthaltende zusammensetzung und stabilisierungsverfahren.
NO964905D0 (no) Substituerte benzendikarboksylsyre-diguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
KR900014372A (ko) 티에닐피페라진 이의 제조방법 및 이를 함유하는 약제
DK174885A (da) Derivater af n-(3-phenylmethylthio-1-oxopropyl)-aminoeddikesyre i form af enantiomere eller blandinger, fremgangsmaade til fremstilling af forbindelserne og laegemiddel indeholdende disse
UA37377A (uk) Спосіб отримання мазі для лікування захворювань, які викликані внутрішньоклітинними інфекційними агентами

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O E 13 DA LPI 9.279/1996

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2015, OBSERVADAS AS CONDICOES LEGAIS.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTES DA NULIDADE: 1O) EMS S.A. - PETICAO NO018160000439 DE 05/02/2016; 2O) ACHE LABORATORIOS FARMACEUTICOS S/A. - PETICAO NO870160006011 DE 23/02/2016. PETICOES DISPONIVEIS NO E-BUSCA.

B25G Requested change of headquarter approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 20/08/2019